2023
Patient Preferences for Postmastectomy Breast Reconstruction
Shammas R, Hung A, Mullikin A, Sergesketter A, Lee C, Reed S, Fish L, Greenup R, Hollenbeck S. Patient Preferences for Postmastectomy Breast Reconstruction. JAMA Surgery 2023, 158: 1285-1292. PMID: 37755818, PMCID: PMC10535024, DOI: 10.1001/jamasurg.2023.4432.Peer-Reviewed Original ResearchConceptsRisk of complicationsBreast reconstructionAbdominal morbidityFlap reconstructionBreast cancerGenetic predispositionPatient-physician discussionsImplant-based reconstructionPostmastectomy breast reconstructionCross-sectional studyChance of complicationsPatient-centered careAdditional operationsHigher educational levelMajor complicationsPreoperative counselingPatient preferencesFlap appearanceTreatment preferencesImplant reconstructionMAIN OUTCOMENew diagnosisPatient valuesComplicationsMean increase
2017
The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients
Cho E, Shammas R, Glener A, Greenup R, Hwang E, Hollenbeck S. The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients. Plastic & Reconstructive Surgery 2017, 140: 1121-1131. PMID: 29176410, DOI: 10.1097/prs.0000000000003841.Peer-Reviewed Original ResearchConceptsBody mass index (BMI) changeAutologous breast reconstructionBody mass index increaseBreast cancer patientsBody mass index (BMI) patternsBreast reconstructionCancer patientsMultivariable regressionNormal baseline body mass indexBaseline body mass indexImmediate autologous breast reconstructionCLINICAL QUESTION/LEVELHigh-risk patientsPropensity-matched pairsBody mass indexRisk of recurrenceWeight management strategiesBaseline obesityAdjuvant therapyTotal patientsMass indexTherapeutic mastectomyMastectomy patientsAutologous reconstructionAuthors' institutionCost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analysesBreast Cancer after Augmentation
Cho E, Shammas R, Phillips B, Greenup R, Hwang E, Hollenbeck S. Breast Cancer after Augmentation. Plastic & Reconstructive Surgery 2017, 139: 1240e-1249e. PMID: 28538550, DOI: 10.1097/prs.0000000000003342.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast ImplantationBreast ImplantsBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMammaplastyMastectomyMiddle AgedMultivariate AnalysisPostoperative ComplicationsReference ValuesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurgical FlapsTime FactorsTreatment OutcomeUnited StatesConceptsPrior augmentationBreast cancer stageBreast cancerSubglandular augmentationCancer stageImplant placementCLINICAL QUESTION/LEVELPreferred reconstructive methodAdvanced breast tumorsTwo-stage implant reconstructionInvasive breast cancerBreast cancer screeningBreast cancer diagnosisUndergoing mastectomySubpectoral implantsDuctal carcinomaTherapeutic mastectomyCancer screeningTreatment recommendationsImplant reconstructionSubpectoral augmentationAuthors' institutionBreast augmentationMastectomyBreast tumors
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomy